Clinical Trial Update: Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME) [Phase 2]

View source ↗

Summary

Phase 2 trial of intravitreal KVD001 for center-involving diabetic macular edema has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• KVD001

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2020-12-08